COSCIENS Biopharma Inc. (CSCIF) Form 6-K — Jul 6, 2026
COSCIENS Biopharma Inc. completed a share capital amendment effective July 3, 2026, combining a 1-for-150 consolidation with a subsequent 50-for-1 split. The net result reduces the number of common shares outstanding by a factor of three, effectively constituting a 1-for-3 reverse stock split. Shareholders holding fewer than 150 pre-consolidation shares received a cash payment of US$1.60 per share in lieu of new shares.
Key figures
- Split ratio
- 50:1
- Cash out amount
- $1.60
- Consolidation ratio
- 1:150
- Net reduction factor
- 1:3
AI analysis
Red flags3 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.